As of Feb 21, 2025, Regeneron Pharmaceuticals, Inc.'s fair value using the Peter Lynch formula is $372.3 per share. The current price of $700.3 suggests Regeneron Pharmaceuticals, Inc. may be overvalued by this metric.

What is Regeneron Pharmaceuticals, Inc. Price to Earnings (P/E) ratio?

As of Feb 21, 2025, Regeneron Pharmaceuticals, Inc.'s P/E ratio is 17.1x. This is calculated by dividing the current share price of $700.3 by the Earnings per Share (EPS) for the trailing twelve months, which is $40.9. The P/E ratio indicates how much investors are willing to pay for each dollar of earnings.

What is Regeneron Pharmaceuticals, Inc. earnings per share (EPS)?

Regeneron Pharmaceuticals, Inc. earnings per share (EPS) for the twelve months ending Feb 21, 2025, was $40.9, a 9.1% growth year-over-year.